Megakaryocyte growth and development factor (MGDF) is a potent inducer of megakaryopoiesis in vitro and thrombopoiesis in vivo. The effects of MGDF appear to be lineageselective, making this cytokine an ideal candidate for use in alleviating clinically relevant thrombocytopenias. This report describes a murine model of life-threatening thrombocytopenia that results from the combination treatment of carboplatin and sublethal irradiation. Mortality of this regimen is 94% and is associated with widespread internal bleeding. The daily administration of pegylated recombinant human MGDF (PEG-rMGDF) significantly reduced mortality (to ECENTLY, A SERIES OF molecules with potent effects on thrombopoiesis have been described. These proteins, called thromb~poietin,l-~ mpl ligand: or megakaryocyte growth and development factor (MGDF),5,6 induce megakaryocyte progenitor cell expansion"" and maturat i~n ,~" .~. " resulting in significant increases in platelet counts in rodent"3312 and primate" systems. Rat and ovine thrombopoietin, porcine mpl ligand, and canine MGDF were isolated from thrombocytopenic plasmas as glycosylated proteins with molecular weights of 19 k D , 31 k D , 28-32 k D , and 25 or 31 k D , These plasma-derived species, which are of significantly less mass than that predicted by the respective animal or human cDNA sequences,"6 appear to be C-terminally cleaved versions of the full-length molec~l e .~,~,~ The mechanism, amino acid site, and biologic consequence of the human protein truncation are not known.
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The in vivo activity of recombinant MGDF that is a Cterminally truncated version of the human cDNA sequence (rMGDF) in normal and mildly thrombocytopenic animals has been previously described." In the study reported here, rMGDF was evaluated for in vivo therapeutic efficacy before and after the covalent attachment of polyethylene glycol to the parent molecule (PEG-rMGDF), a process known as pegylation. Pegylated cytokines often possess significantly increased circulating half lives that can result in increased in vivo potency.I3 A murine model of severe myelosuppression was used as a clinically relevant test of the pegylated compound. In rodents, the myelosuppressive effect of carboplatin, a chemotherapeutic associated with significant thrombocytopenia in h u r n a n~, '~.~~ is accentuated when administered in combination with sublethal irradiation.I6
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and ameliorated the depth and duration of thrombocytopenia. The severity of leucopenia and anemia was also reduced, although it was not clear whether these effects were direct. Platelets generated in response to PEG-rMGDF were morphologically indistinguishable from normal platelets. PEG-rMGDF administered in combination with murine granulocyte colony-stimulating factor completely prevented mortality and further reduced leukopenia and thrombocytopenia. These data support the concept that PEG-rMGDF may be useful to treat iatrogenic thrombocytopenias. 0 1995 by The American Society of Hematology.
Treated animals become severely thrombocytopenic by day 16; without therapy, only 6% of the animals survive. Significant leukopenia is also associated with this treatment, making it an appropriate model for combined treatment with myeloid growth factors. In this setting, the therapeutic potential of PEG-rMGDF alone or in combination with granulocyte colony-stimulating factor (G-CSF) was evaluated.
MATERIALS AND METHODS

rMGDF administration to normal or myelosuppressed mice.
Balb/c mice (female, 8 to 11 weeks of age, and weighing 19 to 21 g) were purchased from Charles River Laboratories (Hollister, CA) and quarantined for at least 7 days before use. For normal mice, rMGDF or PEG-rMGDF was administered subcutaneously in a range of doses for 5 consecutive days. Platelet levels were determined on day 6. Myelosuppression was induced with a combination of carboplatin (Bristol Labs, Princeton, NJ; 1.25 mg/animal, single intraperitoneal dose) followed 4 hours later with sublethal gamma irradiation (500 rad, single dose) on day 0. Cytokines diluted into phosphate-buffered saline (PBS) and 0.1% homologous mouse serum were subcutaneously administered once daily, starting 24 hours (day 1) after the chemotherapyhadiology treatment and throughout the duration of the experiments. The excipient control (placebo) was PBS and 0.1% homologous mouse serum.
Cytokines. A truncated version of rMGDF6.'* was expressed in Escherichia coli cultures and modified by the covalent attachment of polyethylene glycol (PEG-rMGDF). Both rMGDF species were purified to homogeneity before use (Amgen Inc, Thousand Oaks, CA), In vitro, the specific activities of rMGDF and PEG-rMGDF did not differ by more than 25%. Specific activities, based on the peptide molecular weight, were determined with a factor-dependent murine cell line transfected with the human c-mpl gene6 in which 1 U results in half-maximal growth stimulation. Murine recombinant G-CSF was produced at Amgen Inc.
Hematology, Blood samples were taken on the indicated days from a 2-mm incision in the lateral tail vein. Blood cell counts were determined with the Sysmex Cell analyzer (TOA Medical Electronics, Kobe, Japan). Red blood cell (RBC) and white blood cell (WBC) counts were always within the linear range of the instrument. Samples were diluted for platelet determinations, if necessary.
Histopathology. Femurs were removed, fixed overnight in zincbuffered formalin, and then decalcified in a formaldehyde/formic acid solution. The bones were embedded in paraffin and sections were histochemically stained with hematoxylin and eosin. Addition- Durn analysis. Data are presented as the mean 2 SEM. Statistical comparisons were performed using a two-tailed Student's t-test.
RESULTS
The effects of rMGDF and PEG-rMGDF on normal murine blood cell counts. rMGDF and PEG-rMGDF showed different dose-dependent activities in increasing platelet counts in normal mice (Fig 1) . The more biologically active species was PEG-rMGDF, with a responsddose ratio (slope) of 1,997. rMGDF was less biologically active, with a slope of 633. Even at doses of PEG-rMGDF that increased the platelet count fivefold, there were no statistically significant effects on WBC or RBC counts. Table 1 shows the mean values for W C , RBC, and platelet counts in animals receiving PEG-rMGDF (n = 8) or excipient (n = 33) 24 hours after 5 consecutive days of treatment.
The effects of PEG-rMGDF on blood cell counts in myelosuppressed mice. PEG-rMGDF was selected for further evaluation and was administered to mice pretreated with carboplatin and irradiation. Effects on the degree and/or duration of thrombocytopenia are shown in Fig 2. Whereas mice receiving excipient after carboplatin and irradiation showed a 98% reduction in platelet counts by day 15 or 16 (17 ? 2 X 109/L), animals receiving PEG-rMGDF had improved platelet nadirs that occurred by day 9 or 10 (50 t 8 X 109L). Additionally, whereas platelet counts in mice receiving excipient never recovered to normal levels within the 23-day study, those in mice receiving PEG-rMGDF returned to normal by day 19 to 21. Studies comparing the efficacy of human rMGDF and PEG-rMGDF in this murine model were performed. It was necessary to administer 6 times the dose of rMGDF compared with PEG-rMGDF to achieve a similar therapeutic benefit (data not shown).
Platelets produced in response to PEG-rMGDF after carboplatidirradiation were compared with platelets collected from normal animals. In Fig 3 are shown electron micrographs of platelets collected from platelet-rich plasma from normal animals (Fig 3A) or from carboplatidirradiated ani- For (Fig 3B) . The platelets were virtually identical with respect to shape, size, and granule distribution.
PEG-rMGDF was also evaluated in this model for effects on the degree andlor duration of leukopenia and anemia (Fig  4) . The leukopenic nadir in excipient-treated mice occured on day 13 at approximately 6% of normal levels (0.6 2 0.04 X 109L). Administration of PEG-rMGDF did not affect this parameter. However, leukocyte recovery was significantly faster in PEG-rMGDF-treated animals (Fig 4A) . RBC counts in excipient-treated animals decreased to 20% of normal levels by day 23 (1.8 2 0.3 X l0"L). Mice receiving PEG-rMGDF exhibited a substantially milder reduction in RBC, to 60% of normal, which recovered to pretreatment levels by the end of study (Fig 4B) .
The effects of PEG-rMGDF on survival after treatment with carboplatin and irradiation. Treatment with the combination of carboplatin and irradiation was lethal for most animals. Only 6% of excipient-treated animals survived the 23-day study period. In contrast, 86% of animals receiving PEG-rMGDF survived (Fig 5) .
To investigate probable causes of death, histopathology studies were performed on mice treated with carboplatin and irradiation and treated with excipient or PEG-rMGDF for 15 days. Hemorrhagic foci were seen in the gastrointestinal tract, lung, urinary system, and brain in excipient-treated animals, but not in animals receiving PEG-rMGDF. No obvious signs of infection were present in either group at this time point (data not shown).
Sections of bone marrow from both groups are shown in Fig 6. Mice treated with excipient exhibited a 90% loss in marrow cellularity 15 days after carboplatidirradiation ( Fig  6A) and showed an almost total lack of marrow megakaryocytes (Fig 6B) . In contrast, mice treated with PEG-rMGDF possessed 60% to 95% of normal marrow cellularity at this time ( Fig 6C) and had an abundance of marrow megakaryocytes (Fig 6D) . In addition to enhancing megakaryopoiesis, PEG-rMGDF exposure also led to an increase in myelopoietic and erythropoietic activity evident in foci of both lineages in bone marrows of treated mice (Fig 6E) .
The effects of PEG-rMGDF and recombinant murine G-CSF on survival and blood cell counts after carboplatin and irradiation. The combination of PEG-rMGDF and G-CSF (recombinant murine G-CSF) was evaluated in mice pretreated with carboplatin and irradiation (Fig 7) . In this experiment, none of the animals in the excipient-treated or the G-CSF-treated groups survived past day 15. However, 90% of the PEG-rMGDF-treated animals and 100% of the combination-treated animals survived (Fig 7A) .
Animals treated with PEG-rMGDF plus G-CSF and animals treated with PEG-rMGDF alone exhibited similar platelet count kinetics, with nadirs of approximately 30 X 109L at day 9 and with recoveries to normal levels by days 19 to 23. However, by the end of the study, the cytokine combination-treated group had platelet counts that were significantly greater than those in the PEG-rMGDF-treated group (1,669 2 234 X 109L and 497 ? 11 1 X lo9& respectively, P = .01; Fig 7B) .
Because of the mortality in the excipient-treated and G-CSF-treated groups, WBC counts were not available for those animals past day 13. We therefore compared WBC counts in the groups administered the cytokine combination or PEG-rMGDF alone. The leukocyte nadir in the former group was 0.70 ? 0.06 X 109L on day 5 and in the latter group was 0.38 ? 0.05 X 109L on day 8. At the end of study, the combination-treated group had a WBC count of 7.0 2 1.6 X 109L compared with 2.2 ? 0.4 X 109L in the PEG-rMGDF-treated group (Fig 7C) .
The coadministration of PEG-rMGDF plus G-CSF or treatment with PEG-rMGDF alone resulted in virtually identical RBC recovery kinetics (data not shown).
DISCUSSION
Damage to the hematopoietic system is frequently a serious complication of cancer therapy. In particular, damage to neutrophil and platelet progenitors can result in severe clinical consequences such as sepsis and hemorrhage, respectively. The severity and duration of neutropenia in patients can be reduced by administration of myeloid growth facHowever, corresponding cytokines for specific abrogation of thrombocytopenia have not been available. Preclinical and clinical work with cytokines such as interleukin-6 (IL-6),19-'' IL-11,'6.22 IL-3,'9,23 and IL-lZ4 indicate some activity on thrombopoiesis, but amelioration of clinically important thrombocytopenia has not yet been achieved and the potential for adverse events perhaps due to the lack of specificity of these cytokines exists.
The lineage-selectivity of rMGDF and its potent in vitro effects on m e g~o p~i e s i s '~~~~~' '~~~~~ suggest that this molecule may play a significant role in the treatment of thrombocytopenia. This study sought to identify effective rMGDF species that approximated the mass of circulating mammalian Molecules encoded by an N-terminal portion of the human cDNA sequence were produced as nonglycosylated or as pegylated versions. Both preparations had similar in vitro activities, indicating that the C-terminal portion of the molecule was not required for receptorfigand interactions, as previously rep0rted.4'~ However, the in vivo biologic activities of the two preparations were distinct. In particular, pegylation of rMGDF increased the in vivo potency of the molecule in normal animals roughly 20-fold. In preliminary studies, the circulating half-life of PEG-rMGDF was approximately 10 times that of r-MGDF (Cheung et al, unpublished data). Although other biophysical properties may also contribute to the improved efficacy of the pegylated molecule, the increase in the half-life must be considered as a primary r e a~o n . '~,~~ PEG-rMGDF was evaluated further in a clinically relevant model of life-threatening thrombocytopenia. The model, which was more severe than a similar model developed by Leonard et a l , I 6 used a combination of carboplatin and irradiation that induced severe myelosuppression, almost complete depletion of the red marrow, and widespread bleeding. In these experiments, mortality was almost 100% and correlated in time to the pancytopenic nadir. Although the definitive cause(s) of death is not known, the presence of microscopic hemorrhagic foci in multiple organs at a time when the survival was decreasing sharply from 50% to 0% strongly imply hemorrhagic complications.
PEG-rMGDF was effective at reducing mortality from 100% to 14% and in alleviating thrombocytopenia in this setting. PEG-rMGDF in combination with G-CSF eliminated the mortality and significantly shortened the duration of leukopenia as well. Interestingly, administration of PEGrMGDF alone lessened the leukopenic duration. This observation was reproducibly observed in PEG-rMGDF-treated animals in comparison to the relatively few excipient-treated animals that survived to the point at which leukocyte recovery could be measured (day 19). The anemia caused by carboplatin and irradiation was also improved by administration of PEG-rMGDF. The available data do not allow a distinction between PEG-rMGDF acting either to stimulate erythropoiesis or to reduce bleeding. Enhanced erythropoiesis was observed in the marrows of myelosuppressed animals receiving the cytokine, supporting a direct or indirect action of PEG-rMGDF on the RBC lineage. Alternatively, the 24-day RBC survival time in myelosuppressed mice was significantly shorter than normal (50 to 60 days):' implying RBC losses through bleeding. RBC recovery in PEGrMGDF-treated mice occurred at a time when platelet counts were returning to normal (after day 15). The apparent benefits of PEG-rMGDF treatment to myeloid and erythroid recovery postmyelosuppression must be interpreted with caution at this point because it is not clear whether the effects are direct or due to the fact that the (many) surviving animals in the PEG-rMGDF-treated group had significantly fewer complications caused by thrombocytopenia compared with the (few) survivors in the excipient-treated group. The hematologic microenvironments of the two groups of survivors would be expected to be distinct.
PEG-rMGDF is a molecule that has tremendous potential for the treatment of thrombocytopenia associated with cancer therapies. Studies evaluating the relationship of senun MGDF levels to platelet counts in human7 and rodenf+1235*29 models of platelet recovery and work with mpl-deficient mice3' suggest that native thrombopoietin is an important physiologic regulator of thrombopoiesis. In a murine model of moderate thrombocytopenia induced by carboplatin alone, For personal use only. on October 27, 2017. by guest www.bloodjournal.org From rMGDF completely prevented thrombocytopenia.'* However, because spontaneous bleeding in patients does not usually occur until platelet counts are severely suppressed, a more clinically relevant model of thrombocytopenia and its complications was required. The present study shows the unambiguous efficacy of PEG-rMGDF in a clinically relevant setting of severe thrombocytopenia. It also shows that G-CSF offers additional beneficial hematopoietic effects and that the combination is best for reducing myelosuppression and preventing mortality. This study provides a rationale for clinical studies of PEG-rMGDF alone or in combination with G-CSF.
